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Abstract: G protein-coupled receptors (GPCRs) are important cell signaling mediators, 
involved in essential physiological processes. GPCRs respond to a wide variety of ligands 
from light to large macromolecules, including hormones and small peptides. Unfortunately, 
mutations and dysregulation of GPCRs that induce a loss of function or alter expression 
can lead to disorders that are sometimes lethal. Therefore, the expression, trafficking, 
signaling and desensitization of GPCRs must be tightly regulated by different cellular 
systems to prevent disease. Although there is substantial knowledge regarding the mechanisms 
that regulate the desensitization and down-regulation of GPCRs, less is known about the 
mechanisms that regulate the trafficking and cell-surface expression of newly synthesized 
GPCRs. More recently, there is accumulating evidence that suggests certain GPCRs are 
able to interact with specific proteins that can completely change their fate and function. 
These interactions add on another level of regulation and flexibility between different 
tissue/cell-types. Here, we review some of the main interacting proteins of GPCRs.  
A greater understanding of the mechanisms regulating their interactions may lead to the 
discovery of new drug targets for therapy. 
Keywords: GPCR; interacting protein; chaperone; escort protein; accessory protein; 
signaling modulation; trafficking 
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Abbreviations 
5-HT, 5-hydroxytryptamine; 5-HTR, 5-HT receptor; δ, κ, μ receptors, δ, κ, μ opioid receptors; 
ACTH, adrenal corticotrophic hormone; ADM, adrenomedullin; AM receptor, adrenomedullin 
receptor; AT1 receptor, angiotensin II receptor type 1; CaM, calmodulin; cAMP, cyclic AMP; CGRP, 
calcitonin gene-related peptide; CLR, calcitonin receptor-like receptor; CRF1 receptor, corticotropin 
releasing factor receptor 1; CRF, corticotropin releasing factor; CT, calcitonin; CTR, calcitonin receptor; 
DLG1, disks large homolog 1; D receptor, dopamine receptor; DRiP78, dopamine-receptor-interacting 
protein of 78 kDa; ER, endoplasmic reticulum; ErbB1, epidermal growth factor receptor; FGD, 
familial glucocorticoid deficiency; GASP, GPCR-associated sorting protein; GPCR, G protein-coupled 
receptor; GPK, GPCR kinase; HSP, heat shock protein; IAPP, islet amyloid polypeptide;  
MCR, melanocortin receptor; MRAP, melanocortin 2 receptor accessory protein; MSH,  
melanocyte-stimulating hormone; mGlu receptor, metabotropic glutamate receptor; NHERF, Na+/H+ 
exchanger regulatory factor; ninaA, neither inactivated nor after potential A; ODR-4, odorant protein 
4; OR, odorant receptor; PAR, proteinase-activated receptor; PDZ, postsynaptic density protein 95, 
drosophila disc and zonula occludens protein 1; PKC, protein kinase C; PLC, phospholipase C; PTH, 
parathyroid hormone; RAMP, receptor activity-modifying protein; RanBP2, Ran binding protein 2; 
RCP, receptor component protein; REEP, receptor expression enhancing protein; Rh1, rhodopsin 1; 
RTP, receptor transporting protein; SNX, sorting nexin; VIP, vasoactive intestinal peptide; V2 
receptor, vasopressin 2 receptor; VPAC receptor, VIP and pituitary adenylate cyclase-activating 
polypeptide receptor; Yip, Ypt-interacting protein. 
1. Introduction 
The largest family of cell-surface receptors is the superfamily of the G protein-coupled receptors 
(GPCRs). The GPCR family is characterized by its seven transmembrane spanning domains and 
represents the largest class of drug targets. There are more than 800 known GPCRs in the human 
genome, which are involved in virtually every physiological process [1]. GPCRs can be divided into 
five subfamilies: the rhodopsin (originally called A or I), secretin (B or II), glutamate (C or III), 
adhesion and frizzled/taste2 [1]. GPCRs can be activated by a wide range of stimuli, such as photons 
of light, odorant molecules, peptides, hormones and lipid molecules [2]. 
GPCRs play a central role in cell signaling and it is vital for organisms to maintain the right balance 
between activation and desensitization. Therefore, GPCRs must be carefully regulated by the many 
different cell systems in which they are present. In order for signal transduction to be initiated by a 
GPCR, it must be present at the cell-surface. This prerequisite provides a mechanism for regulation. 
Only a few GPCRs are known to possess an identified N-terminal endoplasmic reticulum (ER)-export 
signal, which promotes trafficking to the cell-surface. Furthermore, exit from the ER also requires 
correct folding of GPCRs, which is promoted by chaperone proteins. Improper folding leads to 
retention of GPCRs in ER and/or targeting to the proteasome for degradation [3–5]. The concept of 
chaperones was first proposed in 1987, to define a class of proteins involved in the correct folding of 
newly synthesized proteins [6]. Heat shock proteins (HSPs) are commonly considered as the central 
components of this system. In general, HSPs recognize hydrophobic domains exposed by unfolded 
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proteins and prevent inappropriate association or aggregation of these domains, subsequently promoting 
the correct folding of these proteins [7]. HSPs were originally identified as being upregulated after heat 
shock or other stresses promoting survival of the organism [8]. Such stress events can potentially 
modify a protein’s properties, promoting an “unfolded” protein state that has a higher probability of 
reaching an irreversible unfolded state or of forming aggregates that can eventually lead to cell death. 
The HSPs consist of many structurally unrelated protein families [9], where the HSP70 and HSP40 
family are the most characterized. HSP40 are co-factors of the HSP70 that comprise a J-domain 
allowing the recruitment and the ATPase activity of the HSP70 [10]. 
Small cell-permeable compounds known as pharmacological chaperones are able to rescue 
mutation-mediated misfolding of vasopressin 2 (V2) receptor, involved in diabetes [11] and rhodopsin 1 
(Rh1) receptor, involved in retinitis pigmentosa [12]. These pharmacological chaperones are believed 
to bind to newly synthesized receptors, stabilizing their structure to enable normal trafficking to the  
cell-surface. As well as quality control for exit from the ER, interactions with specific molecular 
chaperones and GPCRS is known to promote trafficking to the cell-surface, maturation and even 
modulate the signaling of these receptors. 
GPCRs transfer extracellular signals across the plasma membrane to intracellular effectors via G 
proteins. G proteins belong to the GTPase family and consist of three protein subunits, an α-subunit, a 
β-subunit and a γ-subunit. The β- and γ-subunits form a stable dimeric complex referred as the  
βγ-subunit. The binding of the agonist to the GPCR induces a conformational change of the receptor 
promoting activation of heterotrimeric G proteins by interaction with the GPCR. Upon activation, the 
Gα-subunit dissociates from the βγ-subunit complex. Both Gα-subunit and the βγ-subunit complex are 
then free to activate downstream effectors [13,14]. Gα-subunits are divided into four families based on 
similarity of the α-subunits: Gαs, Gαi/o, Gαq/11 and Gα12/13. The Gαs and Gαi/o families activate or 
inhibit the activity of adenylate cyclase resulting in an increase or decrease of cyclic AMP (cAMP) 
production, respectively. The Gαq/11 family stimulates phospholipase C (PLC) that hydrolyzes 
phosphatidylinositol phosphates leading to intracellular Ca2+ mobilization (from the ER) and activation 
of protein kinase C (PKC). Finally, the Gα12/13 family activates small GTPases including the Rho 
family (e.g., RhoA). These second messengers then activate several intracellular pathways to modulate 
cell function [13,15].  
Activation of GPCRs triggers not only activation of G proteins, but also other cellular events that 
lead to a rapid attenuation of receptor responsiveness, a process termed desensitization. Signaling of 
activated GPCRs at the cell-surface must be rapidly terminated in order to prevent uncontrolled 
signaling. The first step in desensitization is phosphorylation of the receptor [16,17], mainly by a 
kinase family named GPCR kinases (GRKs) [18,19]. Since their discovery, GRKs have been shown to 
play a central role in the desensitization of many GPCRs [20]. Further studies identified another 
protein family that was only able to bind phosphorylated GPCRs, called arrestins. The arrestin family 
of proteins comprises four members, arrestin1-4, also known as visual arrestin, β-arrestin1, β-arrestin2 
and cone arrestin, respectively [21,22]. Unlike arrestin 1 and 4, the β-arrestins are ubiquitously expressed 
and play a conical role in the desensitization of many GPCRs. Interaction of β-arrestins with activated 
GPCRs promotes the uncoupling of the GPCR from G proteins, terminating the G protein-dependent 
signaling initiated at the cell-surface. In addition to termination of signaling, β-arrestins also facilitate 
internalization of GPCRs and act as a molecular scaffold recruiting signaling proteins to internalized 
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GPCRs in endosomes to activate G protein-independent signaling cascades. The roles of GRKs and  
β-arrestins in the trafficking and signaling of GPCRs has been extensively studied and are reviewed 
elsewhere [23–27]. 
After internalization, the fate of GPCRs depends on both the cell type and on the type of receptor. 
Typically, following agonist-induced internalization, GPCRs are efficiently recycled back to the  
cell-surface. However, many GPCRs are trafficked to a degradative pathway and proteolytically 
destroyed in the lysosome, a process called down-regulation. Again, the mechanisms involved in this 
process have been the subject of many studies and they are reviewed elsewhere [25,27,28]. 
Table 1. Interacting proteins that influence cell-surface localization of G protein-coupled 
receptors (GPCRs). 
GPCR(s) 
Interacting 
protein(s) 
Function(s) References 
Rh1 receptor ninaA 
Promote correct folding and cell-surface 
expression 
[29–31] 
Red/green opsins RanBP2 
Potentially promote correct folding and  
cell-surface expression 
[32] 
ORs 
RTP1-2 and 
REEP1 
Promote cell-surface expression. Co-localize at 
the cell-surface with ORs 
[33] 
TAS2Rs RTP3-4 Promote cell-surface expression [34] 
δ-μ receptor heterodimer RTP4  Promote cell-surface expression [35] 
5-HT1BR and 5-HT4R S100-A10 Promote cell-surface expression [36,37] 
δ receptor GASPs Promote down-regulation of the receptor [38] 
β2-adrenoceptor GASPs Promote down-regulation of the receptor [38] 
D2 receptor GASPs Promote down-regulation of the receptor [39] 
μ receptor GASPs Promote down-regulation of the receptor [40] 
κ receptor GASPs Promote down-regulation of the receptor [40] 
β1-adrenoceptor GASPs Promote down-regulation of the receptor [40] 
CTR GASPs Promote down-regulation of the receptor [40] 
PAR1 SNX-1 Promote internalization of the receptor [41,42] 
oxytocin receptor  SNX-1 Promote internalization of the receptor [43] 
δ receptor SNX-1 Promote internalization of the receptor [43] 
Neurokinin 1 receptor SNX-1 Promote internalization of the receptor [43] 
Recent studies have challenged the traditional concepts of GPCR activation, where one ligand 
interacts with one receptor to couple to one G protein and thereby initiating signaling. In fact, we now 
understand that different ligands can interact with same GPCR to stabilize different receptor conformations. 
This ligand-specific conformation of the GPCR then promotes unique signaling properties. During 
their “life”, GPCRs have been shown to interact with many proteins. These interactions are important 
to regulate GPCRs and maintain the correct balance between signaling and desensitization. There is 
now increasing evidence that many GPCRs interact with specific interacting proteins that alter their 
expression, function and fate. These proteins are often referred as “accessory” or “escort” proteins and 
how the specific interactions with these accessory proteins lead to critical changes in GPCR expression 
and signaling constitutes the topic of this review. It must be noted that many GPCRs have been shown 
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exist as homo- or hetero-dimers (or even higher order oligomers) and that these interactions are 
important for modulating the functional properties of GPCRs. Therefore, GPCRs themselves can be 
considered as accessory proteins. However, only non-GPCR accessory proteins will be discussed  
in this review, but for more details see [44,45]. Here, we review a non-exhaustive list of the  
major GPCR-interacting proteins, and merge some old and new concepts in order to understand  
these mechanisms. 
2. Interacting Proteins that Modulate Cell-Surface Localization of GPCRs 
The appropriate expression and localization of GPCRs is essential so that cells can maintain proper 
communication pathways within an organism. Indeed, dysregulation of process that control if a GPCR 
reaches the cell-surface and if it internalizes or is down-regulated properly can lead to aberrant cell 
signaling and potentially lead to disorders and disease. Studies have revealed that certain GPCRs 
require specific factors to properly regulate their trafficking to or from the cell-surface (Table 1, Figure 1). 
Figure 1. Schematic representation of the roles of GPCR interacting proteins in the 
localization of GPCRs at the cell-surface. (A) NinaA, RanBP2, RTPs, REEPs, ODR-4 and 
protein S100-A10 facilitate cell-surface localization by promoting correct folding  
and protein trafficking; (B) Receptor activity-modifying proteins (RAMPs) act as 
chaperones and traffic with GPCRs to the cell-surface and (C) promote glycosylation of 
the GPCR; (D) Melanocortin 2 receptor accessory proteins (MRAPs) and  
dopamine-receptor-interacting protein of 78 kDa (DRiP78) either promote or prevent  
cell-surface localization depending on the particular GPCR.  represents glycosylation. 
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2.1. ninaA and RanBP2: Modulators of Opsin Receptors 
The Drosophila melanogaster gene ninaA (neither inactivated nor after potential A), was  
initially found to encode a protein required for the biogenesis Rh1 receptor [29,30]. ninaA was shown 
to share sequence homology and function with cyclophilin A, a protein that exhibits a peptidyl-prolyl 
cis-trans isomerase activity and is involved in the folding of proteins [30,46]. Knockout studies of 
ninaA showed that the Rh1 receptor is retained in ER and unable to traffic to the cell-surface in 
absence of ninaA [31]. The Rh1 receptor and ninaA form a stable complex in vivo and mutations in 
ninaA are sufficient to promote a significant reduction in the presence of Rh1 receptors at the  
cell-surface [31,47]. The observation that the Rh1 receptor and ninaA form a stable complex and  
co-localize in different vesicles within the cytoplasm, suggests that ninaA is an escort protein that is 
required for the proper folding and trafficking of Rh1 receptors [31,47]. In fact, ninaA was the first 
“private” chaperone described for a GPCR. 
RanBP2 (Ran binding protein 2) is the mammalian homologue of ninaA, which is also specifically 
expressed in photoreceptor cells. RanBP2 interacts with red/green opsins and is believed to have 
similar function that its homologue. However, unlike ninaA, the cyclophilin domain of RanBP2 does 
not directly bind to the opsin receptor, but augments binding to its Ran binding domain 4 (RBD4) [32]. 
2.2. RTPs and REEPs: Traffic of the Odorant Receptors 
Even though the existence of mammalian odorant receptors (ORs) has been known for  
over 20 years [48], studies have been hampered, simply because of their lack of expression at the  
cell-surface of heterologous cells. The reason behind this is that when expressed in model cell systems 
they are retained in the ER and then degraded by the proteasome [49,50]. These observations raised the 
question that perhaps ORs require specific accessory proteins to regulate their expression at the  
cell-surface. A study using Caenorhabditis elegans showed that the transport of ORs to the cilia of 
olfactory neurons required the expression and association of ORs with a transmembrane protein called 
odorant protein 4 (ODR-4) [51]. It has been subsequently found that co-transfection of rat ORs with 
ODR-4 in immortalized olfactory sensory neurons from rat, called odora cells [52] and CHO cells 
enhances the transport and expression of ORs at the cell-surface [53]. These studies suggested that 
olfactory neurons have a selective molecular machinery that promotes expression of ORs at the cells 
surface [53,54]. In an attempt to identify new accessory proteins involved in the trafficking of ORs to 
the plasma membrane, single olfactory neurons and neurons from the vomeronasal organ of mouse 
were screened for genes that encode membrane-associated proteins. Potential candidates were then 
cloned and co-transfected in HEK293T cells with a mouse OR, MOR203-1 [33]. This study identified 
two protein families able to facilitate expression of MOR203-1 at the cell surface. Receptor 
transporting protein 1 and 2 (RTP1, RTP2) both strongly induced expression of several ORs at the  
cell-surface. The receptor expression enhancing protein 1 (REEP1) appeared to also promote  
cell-surface expression, but to a much smaller extent compared to RTP1 and 2 [33]. 
Interestingly, these accessory proteins are specifically expressed in olfactory neurons, not even in 
testis, where a subsets of ORs are expressed [55,56], suggesting the presence of a cell-specific mechanism 
that regulates transport of ORs to the cell-surface in testis. Indeed, other members of the RTP and 
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REEP families show a more widespread distribution than the olfactory sensory neurons. For instance, 
RTP3 is expressed in liver, lung, and testis, whereas RTP4 and several REEP gene are expressed in 
amygdala, bladder, bone marrow, colon, kidney, liver, lung, lymph node, macrophages, mammary 
gland, melanocytes, nasopharynx, pituitary, prostate, retinal pigment epithelium, spinal cord, spleen, 
testis, thymus and uterus [34]. However, RTP3 and RTP4 have not been shown to promote cell-surface 
expression of ORs in testis, but to another class of GPCRs, the bitter taste receptors, TAS2Rs [34]. 
Although, δ and μ opioid receptors (δ and μ receptor) are expressed at the cell-surface when 
transfected separately in HEK293 cells (e.g., [57]), it has been reported that when they are co-transfected 
they form a heterodimer that is, retained in the trans-Golgi apparatus, ubiquitinated and degraded by 
the proteasome [35]. However, expression of RTP4 enhances cell-surface localization of δ-μ receptor 
heterodimer and subsequently prevents its ubiquitination and degradation [35]. 
Recently, sequence comparisons showed that REEP shares structural homology with the plant 
protein HVA22s and the yeast protein YOP1P both of which belong to the Ypt-interacting protein 
(Yip) family. Therefore, REEP was reclassified as part of this family [58]. Yips are transmembrane 
proteins that bind to Rab proteins. Their exact functions remain unknown; however Yip3 members 
have been showed to be involved in the vesicular transport [59]. Studies have shown that REEP1 and 
REEP5 (also known as DP1) are involved in shaping the ER by linking microtubule fibers to the  
ER [58,60]. A recent study looking at the role of REEP in the trafficking of α2A- and α2C-adrenoceptors 
showed that REEP1-2 and 6 enhance the cell-surface expression of α2C-adrenoceptors, but not  
α2A-adrenoceptors, by increasing the capacity of ER cargo, thereby allowing more receptors to reach 
the cell-surface [61]. Unlike RTP1, REEP1-2 and 6 are only present in the ER, do not traffic to the 
plasma membrane and specifically interact with the minimal/non-glycosylated forms of α2C-adrenoceptors 
through an interaction with its C-terminus [33,61]. Thus, REEPs seem to function as important 
modulators of the ER, rather than specific GPCRs-interacting proteins. 
Even though much has been learned about the role of RTP family proteins in the trafficking of 
GPCRs, the exact mechanisms by which RTPs promote trafficking remain poorly understood. For 
example, it is not known if RTPs facilitate the transport of GPCRs through specific vesicles/cargo, as 
has been described for REEPs. Moreover, given that RTP1 and ORs form a complex at the  
cell-surface [33], it is possible to imagine that RTPs are able to modulate the ligand binding of GPCRs. 
However, RTPs do not seem to affect ligand specificity of two mouse ORs [33]. Nonetheless, this 
possibility cannot be excluded for other GPCRs. The wide distribution of RTPs implies that they are 
likely to be involved in the regulation of yet unidentified GPCRs. 
2.3. Protein S100-A10 and Its Role in Depression 
Protein S100-A10 (also known as p11) was first identified as part of a heterotetrameric complex 
with annexin A2, a protein involved in the linkage of the actin cytoskeleton to membrane-associated 
proteins [62]. Protein S100-A10 was subsequently found to interact with many other proteins, including 
ion channels (e.g., NaV1.8 sodium channel and TASK1 potassium channel [63,64]), proteolytic enzymes 
(e.g., cathepsin B and the plasminogen activator [65,66]) and GPCRs (e.g., 5-Hydroxytryptamine (HT) 
1B and 5-HT4 receptors [36,37]). Protein S100-A10 belongs to the S100 EF-Hand protein family, the 
largest group of the superfamily of proteins containing a Ca2+-binding domain called EF-Hand  
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motif [67]. S100 are small acidic proteins (10–20 kDa) that exist as homo- and heterodimers, where 
each monomer contains two EF-Hand motifs. However, protein S100-A10 is unique in the fact that it 
has two mutations in its two EF-Hand motifs, which makes it unable to bind Ca2+ [67]. Protein  
S100-A10 is mainly expressed in regions of the brain that are involved in the pathophysiology of 
depression, such as the nucleus accumbens, cerebral cortex and hippocampus [68–70]. Therefore, it 
was hypothesized that protein S100-A10 may play a role in depression (reviewed in [71]). The 
pathophysiology of depression remains unclear, however, dysregulation of 5-HT receptors (5-HTRs) 
have shown to be important in the development of the disease [72]. 
Studies looking for a link between protein S100-A10 and 5-HTRs observed that protein S100-A10 
binds to the third intracellular loops of 5-HT1BR and 5-HT4R [36,37]. They also reported that when  
5-HT1BR and 5-HT4R were transfected in COS-7 cells, their cell-surface expression was increased 
when co-transfected with protein S100-A10. Likewise, protein S100-A10 has been shown to  
potentiate the effects of 5-HT on 5-HT1BR- and 5-HT4R-mediated cAMP production, whereas protein  
S100-A10-knockdown reduced the binding of 5-HT to the same receptors. However, the exact 
mechanisms by which protein S100-A10 regulates transport of 5-HT1BR and 5-HT4R to the cell-surface 
remain to be determined. 
Interestingly, patients who had suffered from unipolar major depression disorder were found to 
have lower levels of both protein S100-A10 mRNA and protein, similar observations made in a mouse 
model of depression (H/Rouen mice). Conversely, treatment with two antidepressants, imipramine 
(inhibits 5-HT reuptake) and tranylcypromine (a monoamine oxidase inhibitor that inhibits 5-HT 
degradation), significantly increased levels of protein S100-A10 mRNA [36]. In behavioral studies 
wild-type mice showed increased mobility in the forced swim and tail suspension tests following 
treatment with anpirtoline (5-HT1BR agonist) and RS67333 (5-HT4R agonist) reflecting a decreased in 
the depression state [73,74]. However, protein S100-A10-knockout mice exhibited a reduced mobility 
in similar tests, indicating that these mice present a depression-like phenotype [36,37]. Therefore, 
protein S100-A10 may play an important role in depression, through its ability to modulate 5-HTR 
expression at the cell-surface. Protein S100-A10 has been shown to bind to a wide variety of proteins 
(e.g., annexin A2, peptidases and ion channels), therefore it is likely that protein S100-A10 and other 
members of the S100 protein family also regulate the expression and/or signaling of other GPCRs. 
2.4. GASPs and SNXs: Interacting Proteins in GPCR Down-Regulation 
The removal of GPCRs from the cell-surface is another mechanism to ensure termination of 
signaling. This process is termed endocytosis and controls and regulates the entry and exit of small and 
large molecules. Endocytosis is influenced by GRKs, β-arrestins and ubiquitin (a small regulatory 
protein involved in the degradation of proteins) (reviewed in [23,28,75]). However, the down-regulation 
of GPCRs has also been shown to depend on other accessory proteins (Table 1, Figure 2). 
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Figure 2. Schematic representation of the roles of GPCR interacting proteins in the 
signaling and trafficking of GPCRs from the cell-surface. (A) DRiP78 coordinates the 
assembly of the G protein•GPCR complex to ensure proper GPCR signaling at the  
cell-surface; (B) Following activation of certain GPCRs, CaM regulates GPCR 
phosphorylation; (C) Calmodulin (CaM) and Na+/H+ exchanger regulatory factor (NHERF) 
both act to specify G protein coupling and enhance G protein-dependent signaling;  
(D) Receptor component protein (RCP) specifically interacts with CLR•RAMP complexes 
to enhance signaling; (E) At the cell-surface, RAMPs interact with GPCRs to confer 
agonist specificity; (F) GASPs and SNXs interact with activated GPCRs to promote 
efficient down-regulation and thereby permanently terminate signaling.  
 
The GPCR-associated sorting protein (GASP) family comprises a family of 10 proteins that interact 
with a broad spectrum of GPCRs [76]. The first family member GASP1 was identified as a binding 
partner of the δ receptor [38]. The interaction between δ receptor and GASP1 promotes traffic of the 
receptor to lysosomes, inducing its degradation. Overexpression of cGASP1 (a dominant negative of 
GASP1 consisting of the final 497 residues of the protein) or mutation of the interaction domain of 
GASP1 allows the δ receptor to escape from lysosomal degradation and promotes recycling of the 
receptor. GASP1 also interacts with the C-terminal tails of dopamine 2 (D2) receptors [39], μ and κ 
opioid receptors, β1-adrenoceptors and calcitonin receptors (CTR) [40]. GASP1 is widely distributed, 
but is predominantly expressed in the central nervous system [40]. Interestingly, GASP1 has also been 
found to bind β2-adrenoceptor, a receptor that usually undergoes efficient recycling, a fact that 
suggests that GASP1 may be involved in the sorting of β2-adrenoceptor for down-regulation which 
Int. J. Mol. Sci. 2014, 15 1121 
 
occurs following chronic stimulation [38]. More recently, co-immunoprecipitation together with 
mutagenesis studies reveal a highly conserved and repeated GASP motif (SWFW) that determines the 
interaction between GASPs and GPCRs [77]. Indeed, the discovery of this GASP motif lead to the 
identification of two different classes of GASPs: GASP1-5 contain this motif and generally bind 
strongly to GPCRs (GASP1-5); whereas GASP6-10 does not possess this motif and only weakly bind 
to GPCRs [77]. 
Sorting nexins (SNX) are another protein family involved in the endosomal sorting of GPCRs to 
lysosomes. These membrane-associated proteins are characterized by the presence of a PX domain 
(named after NADPH oxidase domains of p40phox and p47phox), consist of approximately 100–130 
amino acids and have the ability to bind various phosphatidylinositol phosphates [78]. SNXs were first 
implicated in the sorting of the epidermal growth factor receptor (ErbB1), a receptor tyrosine kinase. 
Stimulation of ErbB1 with epidermal growth factor promotes binding of SNX-1 to the receptor and 
induces degradation of ErbB1. Degradation of ErbB1 was enhanced by overexpression of SNX-1 [79]. 
Proteinase-activated receptor 1 (PAR1) was the first GPCR identified to be regulated by interaction 
with SNX-1. The C-terminal tail of SNX-1 acts as a dominant negative and blocks agonist-induced 
trafficking of PAR1 to endosomes [41], suggesting that SNX-1 was required for the trafficking of 
PAR1 to lysosomes. This requirement was later confirmed using siRNA to deplete cells of endogenous 
SNX-1 [42]. SNX-1 has been shown to bind other GPCRs, including the oxytocin receptor and  
δ receptor, both of which are known to undergo lysosomal sorting [43]. Similar to GASP1, SNX-1 has 
been found to bind to members of the tachykinin receptor family (e.g., neuorkinin 1 receptor) and 
acetylcholine receptor (muscarinic) family, which are known to recycle back to the cell-surface [43], 
suggesting a role for SNX-1 in down-regulation of GPCRs following chronic exposure to agonist. 
3. Interacting Proteins that Modulate Cell-Surface Localization and Signaling of GPCRs 
The majority of the proteins described above only modulate the expression of GPCRs. However, a 
few GPCRs-interacting proteins have shown to exert remarkable effects not only on the expression of 
GPCRs, but also on the pharmacology of these receptors (Table 2, Figure 2). Those effects are so 
profound sometimes, that these interacting proteins are considered as co-receptors. These specific 
interacting proteins bring another level of regulation where a single GPCR can display two distinct 
functions depending upon its interaction with distinct accessory proteins. 
Table 2. Interacting proteins that influence both cell-surface localization and signaling of GPCRs. 
GPCR 
Interacting 
protein(s) 
Function(s) References 
CLR RAMPs 
Promote cell-surface expression, receptor glycosylation and induce 
ligand binding specificity 
[80] 
CTR RAMPs Induce ligand binding specificity to IAPP [81,82] 
VPAC1 receptor RAMPs Increase the coupling of Gαq-subunit with the receptor [83] 
PTH1 receptor RAMP2 ? [83] 
Glucagon receptor RAMP2 ? [83] 
PTH2 receptor RAMP3 ? [83] 
VPAC2 receptor RAMPs Increase the coupling of Gαi/o-subunit to the receptor, but RAMP3 [84] 
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Table 2. Cont. 
GPCR 
Interacting 
protein(s) 
Function(s) References 
CRF1 receptor RAMP2 Promote cell-surface expression and increase Ca2+ mobilization [84] 
Calcium Sensing 
receptor 
RAMP1 and 3 Promote cell-surface expression and receptor glycosylation [85] 
MCRs MRAPs 
Regulate differently the cell-surface expression depending on the 
MCR and also can modulate MCR-mediated signaling 
[86–88] 
D1 receptor DRiP78 Retain receptor in ER  [89] 
Muscarinic 
acetylcholine 2 
receptor 
DRiP78 Retain receptor in ER [89] 
Adenosine 1 
receptor  
DRiP78 Retain receptor in ER [90] 
AT1 receptor DRiP78 Promote cell-surface expression [91] 
β2-adrenoceptor DRiP78 Promote the coupling of the βγ-subunit [92] 
Chemokine 
receptor 5 
DRiP78 Retain receptor in ER and promote the coupling of the βγ-subunit [93] 
PTH1 receptor NHERF1-2 
Switch the coupling of Gαs to Gαq of the receptor.  
Inhibit internalization and desensitization of the receptor 
[94,95]  
[96–98] 
LPA2 receptor NHERF2 Potentiate PLC signaling [99] 
P2Y1 receptor NHERF2 Potentiate PLC signaling [100] 
mGlu5 receptor NHERF2 Potentiate PLC signaling [101] 
CRF1 receptor DLG1 
Inhibit receptor agonist-induced internalization and promote 
ERK1/2 signaling 
[102] 
3.1. RAMPs, Co-Receptors of the Calcitonin Receptor Family 
The first GPCR-interacting protein family that influenced both the traffic and the pharmacological 
properties of a GPCR are the receptor activity-modifying proteins (RAMPs). The RAMPs are single 
pass transmembrane proteins initially identified as molecular partners of the calcitonin receptor-like 
receptor (CLR, [80]). Agonists of CLR belong to the calcitonin peptide family that includes calcitonin 
(CT), islet amyloid polypeptide (IAPP, also known as amylin), calcitonin gene-related peptide 
(CGRP), adrenomedullin (ADM) and ADM-2 (also known as intermedin). This family of peptides 
exhibits similar biological properties on a wide range of tissues. Some of them are involved in diverse 
pathologies, including diabetes (IAPP, [103]), migraine (CGRP, [104]) and osteoporosis (CT, [105]). They 
all signal through either the calcitonin receptor (CTR) or CLR. Both GPCRs belong to the secretin 
family (also known as class B) [1]. CTR was first cloned in 1991 [106], shortly followed by the 
cloning of CLR [107]. CLR was first believed to be a receptor for either CGRP or IAPP receptor, 
peptides that until then, had unknown receptors [107]. However, CLR was then considered an orphan 
receptor, as functional experiments failed to demonstrate that any peptides of the calcitonin peptide 
family had an activity when CLR was transfected into COS-7 cells [108]. It was a year later that 
evidence of CGRP binding and CGRP-dependent cAMP activation was observed in HEK cells transfected 
with CLR [109]. However, the major breakthrough occurred two years later, when it was shown that 
when RAMPs were necessary to confer receptor function to CLR [80]. The RAMP family comprises 
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three proteins named RAMP1-3, that share ~30% homology and consist of a single transmembrane 
domain with a large extracellular N-terminal and a short intracellular C-terminal [80]. If expressed on 
their own, neither RAMPs nor CLR traffic to the cell-surface and are retained in ER. It is only when 
CLR and RAMPs are co-expressed do they efficiently traffic to the cell surface [80,110]. RAMP1 is 
required to promote terminal glycosylation of CLR, whereas RAMP2 and 3 only promote core 
glycosylation of CLR [80,111,112]. Beyond the roles of RAMPs in protein trafficking and 
glycosylation of CLR, RAMPs are also responsible for the ligand binding specificity of the receptor. 
Indeed, the N-terminal of RAMPs lies close and forms the ligand binding pocket with CLR [112]. 
When CLR associates with RAMP1, it forms a high affinity receptor for CGRP (CGRP receptor). 
Alternatively, when CLR associates with either RAMP2 or 3, they form two distinct high affinity 
receptors for ADM (termed AM1 and AM2 receptors, respectively) [80,113]. It is also interesting to 
note that RAMPs influence agonist-induced internalization of CLR. Sequence analysis indicates  
that RAMP3, but not RAMP1 or 2, possesses a PDZ domain (a protein-protein binding domain, see 
Section 3.5) in its C-terminal that binds to NSF and promote the recycling of AM2 receptor after 
internalization [114]. Moreover, another study has shown that CGRP receptor can either recycle or be 
down-regulated depending on the duration of the stimulus [115]. 
Unlike CLR, CTR traffics to cell-surface when expressed alone and forms a fully functional 
receptor responsive to CT [106]. However, RAMPs have been shown to also interact with  
CTR [81,82], where its association with RAMPs forms three different IAPP receptors (termed  
amylin1–3 receptors). A unique receptor for ADM2 has not yet been defined; however, ADM2 can 
activate CGRP and AM1–2 receptors, as well as IAPP receptors. Although, the highest affinity receptor 
observed for ADM2 is AM2 receptors [116]. Therefore, RAMPs enable a complex system of 
pharmacological diversity with only two GPCRs. Moreover, the promiscuity of the calcitonin peptide 
family for the receptors of the CTR, CLR and RAMP system could also explain the observed similarity 
in the biological effects of these peptides [82]. It certainly suggests that these receptors must be tightly 
regulated in order to present the correct cellular phenotype.  
3.2. RAMPs, Beyond the Calcitonin Receptor Family 
Studies have established that RAMPs are more widely distributed than both CTR and  
CLR [80,117–119], suggesting additional potential roles for RAMPs with other GPCRs. Further, 
studies with Ramp2(−/−) mice have revealed distinct roles for these proteins. For example, knockout of 
Ramp2 is embryonic lethal, with the mice suffering from extreme generalized edema formation and 
blood vasculature abnormalities, similar to Adm(−/−) and Clr(−/−) mice [120–123]. Moreover, Ramp2(−/+) 
mice showed more extended phenotypes than Clr(−/+) mice, suggesting that RAMP2 has additional 
functions. On the other hand, Ramp1(−/−) and Ramp3(−/−) mice are viable and display distinct 
phenotypes. Ramp1(−/−) mice have hypertension and display dysregulated immune responses, whereas 
Ramp3(−/−) mice appear normal until old age, at which point they have decreased weight, indicating 
defects in metabolism [122,124]. Together, these facts imply that RAMPs could potentially interact 
with other GPCRs. Thus, studies have sought to investigate this possibility. It is now known that 
RAMPs interact with at least four other members of the secretin GPCR family. All three RAMPs have 
been shown to bind to VPAC1 receptor (a receptor for vasoactive intestinal peptide (VIP) and pituitary 
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adenylate cyclase-activating polypeptide), whereas RAMP2 also binds to parathyroid hormone 1 
(PTH1) receptor and glucagon receptor and RAMP3 also binds to PTH2 receptor [83]. No evidence 
had yet been found for interactions between RAMPs and VPAC2 or either the glucagon-like peptide 
1receptor or glucagon-like peptide 2 receptors. However, unlike to CLR, expression of RAMPs did not 
affect the cell-surface localization of VPAC1 receptor or binding of VIP to the receptor. VPAC1 
receptor is known to signal through multiple G proteins, leading to cAMP production and activation of 
PLC and subsequent mobilization of intracellular calcium [125]. Quantification of these second 
messengers indicated that RAMP2 in particular, increased the hydrolysis of phosphatidylinositol 
phosphates, without affecting cAMP production. These results suggest that RAMP2 is able to promote 
coupling of VPAC1 receptor with Gαq-subunit [83]. The effect of RAMPs on the signaling properties 
of PTH1, PTH2 and glucagon receptor remains to be determined.  
Although experiments first showed that RAMPs did not interact with VPAC2 receptor [83], a 
different line of experimentation observed that expression of VPAC2 receptors appeared to enhance the 
cell-surface expression of all three RAMPs, without modification of its own trafficking [84]. Further, 
VPAC2 receptor-mediated cAMP production did not show any differences when RAMPs were  
co-transfected. In accordance with this, co-expression of RAMPs had no effects on Gs coupling. 
However, expression of RAMP1 and 2 significantly increased basal coupling of Gαi/o/t/z-subunit to the 
receptor, the functional relevance of this remains unclear. The same study also revealed that RAMP2 
could promote trafficking of corticotropin-releasing factor receptor 1 (CRF1) to the cell-surface. 
Similar to the VPAC2 receptor, RAMP2 had no effect on the coupling of CRF1 receptor to Gαs-subunits, 
but did enhance coupling to Gi/o/t/z, Gq/11 and G12/13 subunits. They also determined that CFR1-induced 
increases intracellular calcium were dependent on Gi/o/t/z subunits and relied on the entry of calcium 
from outside of the cell. These effects on calcium levels were observed when corticotrophin releasing 
factor (CRF) and urocortin were used as agonists and not sauvagine [84], a potent vasoactive peptide 
isolated from frog skin [126]. This study concluded by examining the CRF responses in Ramp2(−/+) 
mice. The researchers observed blood levels of adrenal corticotrophic hormone (ACTH) were reduced 
in response to CRF, compared to Ramp2(+/+) mice. 
These results suggest that RAMPs play an important role in the regulation and signaling of many 
GPCRs belonging to the secretin GPCR family. However, RAMPs have also been shown to regulate a 
receptor of the glutamate GPCR family. The Ca2+-sensing receptor is retained in ER when transfected 
in COS-7 cells, but co-transfection with RAMP1 or 3, not only promotes trafficking of Ca2+-sensing 
receptor to the cell-surface, but also similar to CLR, induces terminal glycosylation of the receptor [85]. 
RAMP2 had no effect on the trafficking of this receptor. 
Overall, there is an abundance of evidence showing that RAMPs enable trafficking as a chaperone 
and also participate in the signaling of diverse set of GPCRs. There may yet be other unknown interactions 
of RAMPs with GPCRs, but there is still much to learn from those interactions that we discussed 
above that may lead to the discovery of new therapies for diseases such as migraine or diabetes. 
3.3. MRAPs and Their Vital Role in Stress 
Stress plays an important part in animal survival. It is defined by the real or perceived threat to 
homeostasis. Stress stimuli promote release of glucocorticoids from the adrenal glands, which induce a 
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wide range of biological responses that include increased cardiovascular tone, respiratory rate, intermediate 
metabolism, immunity and inhibition of general vegetative functions such as feeding, digestion, 
growth and reproduction [127]. Due to the effects of the glucocorticoids on the body, dyregulation of 
systems that regulate their release can lead to health threats such as psychiatric disorders (e.g., depression 
and schizophrenia), Cushing’s syndrome and sepsis [128] and therefore is tightly regulated, mainly by 
the hypothalamic-pituitary-adrenal axis. Stress leads to the activation of the hypothalamic paraventricular 
nucleus, which promotes the secretion of CRF and arginine vasopressin into the hypophyseal  
portal circulation [129]. Both CRF and arginine vasopressin then trigger the release of ACTH [130]. 
ACTH is derived from the cleavage of its precursor proopiomelanocortin together with α-, β- and  
γ-melanocyte-stimulating hormones (MSHs) and endorphin [131,132]. Once released in the 
circulation, ACTH acts mainly on the adrenal gland to stimulate glucocorticoids hormone production. 
Signaling of ACTH and MSHs is mediated by melanocortin receptors (MCRs), a subfamily of the 
rhodopsin GPCR family [133,134]. There are five known members of MCRs, which present different 
tissue distribution and specificity of ligand [135]. All MCRs respond to all proopiomelanocortin-derived 
hormones (i.e., ACTH and α-, β- and γ-MSHs), albeit with different affinities. However, MC2R  
only responds to ACTH [133]. MC2R is predominantly expressed in the adrenal gland, where  
ACTH-dependent activation promotes production and secretion of glucocorticoid hormones [134]. 
Failure of MC2R to respond to ACTH causes a hereditary disease, called familial glucocorticoid 
deficiency (FGD) [136]. This is a rare disorder caused by a single point mutation in MC2R, resulting 
in loss of function. The loss of function is brought about by the receptor’s failure to traffic appropriately 
to the cell-surface [137]. FGD patients generally present profound hypoglycaemia or overwhelming 
infections and the disease normally is lethal in early childhood if left untreated [138]. Mutations in 
MC2Rs account for approximately 25% of all FGD cases and are defined as FGD type 1 [139]. Similarly 
to ORs, the study of MC2R in heterologous cells was difficult also because of its lack of expression at 
the cell-surface. Transfection of MC2R alone resulted in its retention in ER [140]. Therefore, investigators 
hypothesized that MC2R traffic to the plasma membrane was regulated by additional factors. 
FGD patients that had a normal MC2R gene, but still lacked cell-surface expression were  
identified. The patients’ DNA was genetically screened and a number of nonsense splice site mutations 
were identified in C21ORF61 gene [86]. This gene was found to encode a small transmembrane 
protein that is highly expressed in the adrenal gland. Furthermore, once cloned, it was shown to 
interact with MC2R and thus was named melanocortin 2 receptor accessory protein 1 (MRAP1) [86]. 
Co-transfection of MC2R and MRAP1 in CHO cells results in the translocation of MC2R to the  
cell-surface [86]. MRAP consists of 172 amino acids containing a highly conserved N-terminal, a 
single transmembrane domain and a less conserved C-terminal domain [86]. MRAP1 presents a unique 
topology, by forming an antiparallel homodimer [141], which then forms a stable heterodimer with 
MC2R at the cell-surface [87]. Interestingly, the N-terminal domain of MRAP1 comprises a  
tyrosine-rich region that is also found in the N-terminal of REEP1, suggesting that this may be a 
common feature involved in GPCR trafficking [142]. Studies have investigated the effects of mutating 
residues within this region. The studies showed that although MRAP1 mutants can still promote traffic 
of MC2R to the cell-surface, they result in the inability of the receptor complex to respond to ACTH, 
suggesting that MRAP1 influences the ligand binding and/or specificity of the MC2R [87]. 
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Recently, a homologue of MRAP was identified and named MRAP2. MRAP2 is more conserved 
between species than MRAP1 and also interacts with MC2R to promote its traffic and influence its 
signaling [88]. Both MRAP1 and 2 interact with the other MCRs, however the effects on function are 
different to those observed for MC2R. For example, co-transfection of MC4R or MC5R with MRAP1 
and/or MRAP2 in CHO cells results in decrease of cell-surface expression and reduction of [Nle4, 
DPhe7]-α-MSH-mediated signaling of these receptors. MRAPs have no effect on cell-surface localization 
of MC3R, but negatively affect signaling [88]. This data shows that MRAPs are important regulators 
of MCRs function and especially for MC2R in the context of FGD. However, more studies are 
required to clearly assess the role of MRAPs in vivo. Likewise, it would be interesting to investigate if 
MRAPs are able to interact with other GPCRs, which given their wide distribution, is enticing  
to hypothesize. 
3.4. DRiP78, a Regulator of the G Protein•GPCR Complex 
An important step in the expression of transmembrane proteins is their exit from the ER. Generally, 
proteins to be exported possess an ER-export motif that is recognized by protein cargos that belong to 
the coat protein complexes. Coat protein complexes then polymerize and form a “bud” that traffics to 
the cell-surface [143]. Several ER-export sequences have already been identified for membrane 
proteins, such as “DxE” for the vesicular stomatitis virus glycoprotein [144] and “FF” for ER-Golgi 
intermediate compartment-53 (ERGIC-53) [145] and the p24 receptor family [146], where mutation of 
these motifs significantly impairs anterograde transport. In comparison, far less is known about  
ER-export motifs present in GPCRs.  
A study on the D1 receptor, not only identified the ER-export motif “FxxxFxxxF” present in its  
C-terminal tail, but also revealed the specific binding of an ER-membrane-associated protein named 
dopamine-receptor-interacting protein of 78 kDa (DRiP78) [89]. DRiP78 comprises of two predicted 
transmembrane domains that co-localize in the ER. Mutation of the ER-export motif leads to retention 
of D1 receptor to ER and subsequently, decreases the dopamine-induced cAMP production [89]. 
DRiP78 (also known as DNAJC14), belongs to the HSP40 family chaperone proteins that contain a  
J-domain, important for the recruitment of HSP70 [10,147]. Given that the ER-export motif found in 
D1 receptor was also conserved in several other GPCRs and DRiP78 is widely expressed throughout 
the body, it was not surprising that DRiP78 also observed to regulate other GPCRs. DRiP78 negatively 
regulates the cell-surface expression of the muscarinic acetylcholine 2 receptor [89] and the adenosine 1 
receptor [90]. Conversely, the angiotensin II receptor type 1 (AT1 receptor) cell-surface expression is 
enhanced by DRiP78 co-transfection [91]. DRiP78 has also been shown to bind to the β2-adrenoceptor, 
but its function is mainly involved in the assembly of the Gβγ protein subunits of this receptor [92]. 
Association of GPCRs with βγ-subunits occurs in the ER, before any interaction with the Gα-subunits 
which is thought to occur outside the ER, but before the Golgi [148]. DRiP78 has been  
shown to specifically and selectively bind to certain γ-subunits and not α- or β-subunits. The 
GPCR•DRiP78•γ-subunit complex protects the γ-subunit from degradation until the stable binding 
with the β-subunit is complete [92]. Similarly, another protein phosducin-like protein has been shown 
to also regulate the G protein assembly by interacting with β-subunits [149,150]. Interestingly, 
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phosducin-like protein has been found to interact with DRiP78, suggesting that both proteins form a 
complex to promote the association of the βγ-subunit [92]. 
Recently, a study from the same group revealed that DRiP78 also regulates the trafficking of the 
chemokine receptor 5 (CCR5). Overexpression of DRiP78 resulted in the retention of the receptor in 
ER and modulated the association of the βγ-subunit to the receptor [93]. Altogether, DRiP78 seems to 
act as quality control point, where DRiP78 ensures correct association of the G protein complex with 
its GPCR before the export from the ER. However, as previously mentioned DRiP78 is also able to 
enhance cell-surface expression of AT1 receptor [91], suggesting that DRiP78 possesses additional 
function. Thus, further investigations are necessary to fully understand the role of DRiP78 in the 
regulation of GPCRs. 
3.5. The PDZ-Domain Containing Family of Proteins 
This family of proteins contains one or more PDZ domains, named after the discovery of the first 
three proteins containing this domain: Postsynaptic density protein 95, Drosophila disc and  
Zonula occludens protein 1 [151]. Although, PDZ proteins do not seem to function as the other 
proteins described above, they are to date, the best characterized of all the GPCRs-interacting proteins 
that modulate GPCR signaling and desensitization (reviewed in [152,153]). For example, the Na+/H+ 
exchanger regulatory factor (NHERF) protein family, also known as Ezrin-Radixin-Moesin-binding 
phosphoprotein 50, are scaffold proteins that link membrane proteins to the cytoskeleton and are also 
involved in the signaling transmission [154]. A yeast two-hybrid assay showed that NHERF2 binds 
strongly to the C-terminal tail of PTH1 receptor through its two PDZ domains [94]. Normally, the 
PTH1 receptor signals through the activation of adenylate cyclase via Gαs-subunits; however, upon 
NHERF2 interaction, PTH1 receptor preferentially couples to Gαq-subunit, induces activation of the 
PLC and mobilization of intracellular calcium [94]. Similar effects were reported for NHERF1 that 
also switches the coupling of PTH1 receptor from Gαs- to Gαq-subunit [95]. In fact, other studies 
reported that NHERF1-2 can bind Gαq-subunit, PLC and PKC [100,155,156], suggesting that NHERFs 
act as a scaffold protein bringing the effectors of the pathway together to facilitate the signal 
transmission. NHERF2 has also been shown to bind to the lysophospholipid receptor 2, [99], P2Y1 
purinergic receptor [100] and the metabotropic glutamate 5 (mGlu5) receptor [101], where NHERF2 
also potentiates the receptor-induced PLC activation, prolonging the intracellular Ca2+ mobilization.  
Interestingly, the role of NHERF is not only limited to the modulation of GPCR signaling. Indeed, 
NHERF1 has been found to bind β2-adrenoceptors and κ receptors to promote efficient recycling of 
these receptors [157,158]. The PDZ domain found in the C-terminal tail of these receptors, when 
inserted into the C-terminal tail of the δ receptor, is sufficient to induce recycling of this receptor that 
normally undergoes efficient down-regulation [159]. Moreover, NHERF1 also regulates the internalization 
and desensitization of the PTH1 receptor, by inhibiting its interaction with β-arrestin2 [96,97]. After 
stimulation with parathyroid hormone, NHERF1 dissociates from the PTH1 receptor, an action, which 
promotes sequestration of PTH1 receptor within cell-surface microdomains. These microdomains are 
associated with the actin cytoskeleton and clathrin and lead to the stabilization of the PTH1 receptor at 
the cell-surface [98]. NHERF1 also plays an important role in the internalization of the P2Y12 receptor. 
In the absence of agonist NHERF1 binds to the C-terminal tail of the P2Y12 receptor, but following 
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exposure to agonist this direct interaction is broken by the recruitment of β-arrestins to the GPCR. 
NHERF1 subsequently binds to β-arrestins promoting the internalization of P2Y12 receptor [160]. 
Another PDZ domain-containing protein with a role in GPCR regulation is Disks large  
homolog 1 (DLG1; also known as synapse-associated protein 97) [161–163]. DLG1 possesses three 
PDZ domains and it has recently been demonstrated to interact with the PDZ domain found within the 
C-terminal tail of the CRF1 receptor [102]. Knockdown of DLG1 did not affect agonist-stimulated 
cAMP generation, but markedly attenuated mitogenic signaling. Furthermore, DLG1 did not efficiently 
internalize with the CRF1 receptor, which perhaps implies a role for β-arrestins in regulating the 
interaction of DLG1 with the CRF1 receptor, similar to that of NHERF1 and the P2Y12 receptor.  
PDZ domain-containing proteins regulate many cellular functions, including modulation of GPCR 
trafficking and signal transduction [153]. There are about 400 proteins containing PDZ domains in 
humans, which may potentially have a role of GPCR regulation [164]. This type of interaction brings 
another level of signaling diversity by allowing one receptor to signal through different Gα-subunits or 
by regulating its cell-surface expression, depending on the cell type. Further understanding the 
interactions between GPCRs and PDZ domain-containing proteins will unravel new mechanisms that 
can be targeted for therapeutic use.  
4. Interacting Proteins That Modulate GPCR Signaling  
It is often observed that GPCRs can couple to different G proteins complex depending on the cell-type, 
thereby modifying their signaling pathways as described previously with the PDZ proteins [165–167]. 
Further studies have provided evidence that other proteins are able to modulate the G protein-mediated 
signaling of GPCRs (Table 3, Figure 2). 
Table 3. Interacting proteins that influence signaling of GPCRs. 
GPCR Interacting protein Function(s) References 
CLR RCP Enhance CGRP- and ADM-mediated signaling [168] 
μ receptor CaM Impair G protein coupling [169] 
D2 receptor CaM Impair G protein coupling [170] 
5-HT2AR CaM Impair G protein coupling [171] 
PTH1 receptor CaM Inhibit Gα-mediated PLC activation [172] 
V2 receptor CaM Enhance Ca2+ mobilization [173] 
mGlu7 receptor CaM Regulate GPCR phosphorylation [174,175] 
4.1. RCP and CLR: Proof Three Is not a Crowd 
There is evidence of another protein that associates with CGRP and AM1–2 receptor. Receptor 
component protein (RCP) was first identified in 1996 through its ability to promote the CGRP-mediated 
responses in Xenopus laevis oocytes [168]. RCP was specific for CGRP and AM1–2 receptor, as it had 
no effect on the signaling of receptors for CT, IAPP, neuropeptide Y, VIP and β-endorphin [168,176]. 
RCP appeared to be highly conserved in mice, rabbits and humans (~82% homology at protein  
level) [177,178]. In parallel, the cloning and expression of CLR in HEK cells showed evidence of 
CGRP binding and CGRP-induced cAMP production [109], but not in COS-7 cells [179], suggesting 
the presence of a component in HEK cells that makes CLR a functional receptor. However, when CLR 
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was transfected with RAMPs only in COS-7 cells, it yields a functional receptor [180]. Later studies 
showed that in fact RCP was endogenously found in COS-7 cells [181]. Additionally, the distribution 
of RCP expression in the rat central and peripheral nervous system correlates with that of CGRP [182]. 
The use of an RCP antisense construct transfected in NIH 3T3 cells has been shown to reduce  
ADM-induced activation. However, it had no effect on ADM binding or receptor expression at the 
cell-surface [176,181], suggesting that RCP does not act as a chaperone to target CLR to the  
cell-surface, but rather it facilitates efficient coupling of the receptor to the cellular signaling pathways. 
A recent study reported that RCP physically interacts with the second intracellular loop of CLR and 
inhibition of this interaction leads to decreased CGRP-induced signaling [183]. However, the real 
implications of RCP on the functional complex receptor remain to be determined, as a study in yeast 
strongly suggests that RAMPs alone are sufficient to confer functional activity to CGRP and AM1–2 
receptors [184]. 
4.2. Calmodulin 
Calmodulin (CaM) is a small (17kDa) highly conserved protein involved in sensing Ca2+ ions. It is 
ubiquitously expressed and regulates a diverse set of cellular events. CaM was first identified as an 
enhancer of the activity of cyclic nucleotide phosphodiesterases (enzymes that hydrolize cAMP or 
cyclic guanosine monophosphate) [185,186]. CaM belongs to the EF-Hand-containing protein  
family [187]. The association of Ca2+ with CaM promotes a conformational change in CaM that allows 
CaM to bind to variety of proteins [188]. Not surprinsingly, CaM have been shown to interact with 
many GPCRs, with a plethora of effects on the GPCRs signaling. For example, agonist-mediated CaM 
activation is involved in the inhibition of G protein activity, either by impairing the coupling of  
Gαq-subunit with the receptor, as for the μ receptor [169], the D2 receptor [170] and the 5-HT2AR [171] 
or by blocking downstream effectors of G protein signaling, such as PLC for the PTH1 receptor [172]. 
Interestingly, CaM has also been showed to bind to the V2 receptor, a receptor that usually couples to 
Gαs-subunits. However, CaM did not modify V2 receptor-mediated cAMP production, but enhanced 
the intracellular Ca2+ mobilization [173]. Another role for CaM is in the regulation of GPCR 
phosphorylation. CaM, when associated with Ca2+, can bind to the C-terminal tail of the mGlu7 
receptor, thereby preventing the ability of PKC, cAMP-dependent protein kinase and cyclic guanosine 
monophosphate-dependent protein kinase to phosphorylate a serine residue close to the CaM binding 
site [174,175]. However, the effects of CaM binding to the receptor or the phosphorylation of the  
C-terminal remain unknown. 
Overall, CaM seems to play an important regulatory role in the Ca2+-dependent signaling of  
GPCRs and the mechanisms regulating the GPCR•CaM interaction may offer targets to regulate 
GPCR-dependent signaling. However, the mechanisms that regulate CaM are still poorly understood 
and much work remains to be done to fully understand its role. 
5. Conclusions  
GPCRs are key mediators of cellular homeostasis and must be carefully regulated to avoid any 
unbalance between signaling and desensitization that may result in the manifestation of disease. 
Although, the desensitization and down-regulation of GPCRs have been highly documented, 
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mechanisms regulating the trafficking of GPCRs to the cell-surface remain poorly understood, but are 
nonetheless important. Indeed, mutations within GPCR sequences can cause misfolding, alter location 
and lead to retention in ER and/or degradation of the receptor. These events are involved in diseases 
and disorders, such as diabetes, retinitis pigmentosa and hypogonadotropic hypogonadism [189]. 
Accumulating evidence has shown that certain GPCRs require interactions with specific interacting 
proteins. These “so-called” molecular chaperones play critical roles in the folding, maturation, traffic 
to and from the cell-surface and even participate in the agonist binding properties of GPCRs. 
Additionally, several protein families have been found to modulate the G protein-dependent signaling 
of GPCRs. GPCRs remain important drug targets and one of the major problems of today’s therapeutic 
is the lack of specificity, often resulting in determinental side effects or lack of efficacy. By these 
targeting interacting proteins (which often work through different mechanims, dependent on cell-type), 
these issues may be avoided and so provide an effective and safer strategy for the treatment of  
GPCR-driven diseases. 
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